comparemela.com

Latest Breaking News On - American society for transplantation and cellular therapy - Page 1 : comparemela.com

Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)

Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1

United statesBin chenJohn cunninghamJun saitoCancer centerInternational blood marrow transplant researchHematopoietic cell transplant therapy programExchange commissionEuropean unionEuropean medicines agencyTakeda pharmaceutical company limitedMet its primary efficacy endpointClinically meaningful intestinalFree survivalNew safety signals were seenVedolizumab compared

ASTCT to Present Distinguished Honors at the 2023 Tandem

CHICAGO, Jan. 17, 2023 (GLOBE NEWSWIRE) American Society for Transplantation and Cellular Therapy (ASTCT) will present top awards to leaders in the.

United statesSybiryna korenkovaJennifer kasowiczE donnall thomasFred appelbaumSergiy klymenkoLeslie keanFred hutchinson cancer centerNational cancer instituteAmerican society for transplantationCellular therapyTandem meetingsCellular therapy meetingsExecutive vice presidentAmerican societyAmerican society for transplantation and cellular therapy

vimarsana © 2020. All Rights Reserved.